Compare Stocks: ALMS, SMMT, KRYS, and IONS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$11.36 +9.8%	$25.63	$3.76 ▼ $31.35	$1.34B	-0.81	2.70 million shs	7.55 million shs
IONS Ionis Pharmaceuticals	$58.13 -5.2%	$61.71	$50.01 ▼ $86.74	$10.19B	0.42	2.16 million shs	4.34 million shs
KRYS Krystal Biotech	$371.47 +0.6%	$350.09	$136.73 ▼ $382.54	$10.93B	0.54	203,785 shs	226,481 shs
SMMT Summit Therapeutics	$17.13 +17.3%	$14.17	$12.07 ▼ $29.23	$11.65B	-1.24	5.58 million shs	14.88 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+9.76%	-51.06%	-58.11%	-40.40%	+142.74%
IONS Ionis Pharmaceuticals	-5.22%	-6.89%	+5.56%	-21.95%	-3.90%
KRYS Krystal Biotech	+0.61%	+3.92%	+14.38%	+23.41%	+147.32%
SMMT Summit Therapeutics	+17.33%	+19.54%	+24.49%	+15.98%	-27.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$11.36 +9.8%	$25.63	$3.76 ▼ $31.35	$1.34B	-0.81	2.70 million shs	7.55 million shs
IONS Ionis Pharmaceuticals	$58.13 -5.2%	$61.71	$50.01 ▼ $86.74	$10.19B	0.42	2.16 million shs	4.34 million shs
KRYS Krystal Biotech	$371.47 +0.6%	$350.09	$136.73 ▼ $382.54	$10.93B	0.54	203,785 shs	226,481 shs
SMMT Summit Therapeutics	$17.13 +17.3%	$14.17	$12.07 ▼ $29.23	$11.65B	-1.24	5.58 million shs	14.88 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+9.76%	-51.06%	-58.11%	-40.40%	+142.74%
IONS Ionis Pharmaceuticals	-5.22%	-6.89%	+5.56%	-21.95%	-3.90%
KRYS Krystal Biotech	+0.61%	+3.92%	+14.38%	+23.41%	+147.32%
SMMT Summit Therapeutics	+17.33%	+19.54%	+24.49%	+15.98%	-27.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.83	Moderate Buy	$33.27	192.89% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$94.15	61.96% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	-1.63% Downside
SMMT Summit Therapeutics	2.44	Hold	$24.07	40.53% Upside

Current Analyst Ratings Breakdown

Latest ALMS, SMMT, KRYS, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/2/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00 ➝ $15.00
9/1/2026	ALMS Alumis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
9/1/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/1/2026	ALMS Alumis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/31/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	61.14	N/A	N/A	$3.49 per share	3.26
IONS Ionis Pharmaceuticals	$944M	10.23	N/A	N/A	$2.65 per share	21.94
KRYS Krystal Biotech	$389.13M	28.26	$7.33 per share	50.65	$45.92 per share	8.09
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	46.55	39.81	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest ALMS, SMMT, KRYS, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/29/2026	Q2 2026	IONS Ionis Pharmaceuticals	-$1.08	-$0.69	+$0.39	-$0.69	$189.10 million	$267.95 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
KRYS Krystal Biotech	N/A	8.32	7.96
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
IONS Ionis Pharmaceuticals	93.86%
KRYS Krystal Biotech	86.29%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
IONS Ionis Pharmaceuticals	1.81%
KRYS Krystal Biotech	13.10%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	129.43 million	85.82 million	N/A
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable

ALMS, SMMT, KRYS, and IONS Headlines

Recent News About These Companies

Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.

September 3 at 11:11 PM | seekingalpha.com

Summit packs a punch for Merck's Keytruda — but not everyone is sold

September 3 at 6:11 PM | msn.com

Summit Therapeutics Stock Rises 11%

September 3 at 1:01 PM | rttnews.com

Better cancer therapy than Keytruda? Summit Therapeutics partner's Ivonescimab outperforms in lung cancer study

September 3 at 1:01 PM | msn.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - What's Next?

September 3 at 11:59 AM | marketbeat.com

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet

September 3 at 7:00 AM | seekingalpha.com

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

September 2 at 7:00 PM | businesswire.com

Ten healthcare stocks leading in year-over-year CapEx growth

September 2 at 8:33 AM | msn.com

Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Hold" by Brokerages

September 2 at 1:59 AM | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Trading 4.9% Higher - Here's What Happened

September 1 at 3:00 PM | marketbeat.com

The Manufacturers Life Insurance Company Invests $4.34 Million in Summit Therapeutics PLC $SMMT

September 1 at 4:48 AM | marketbeat.com

Hsbc Holdings PLC Invests $1.78 Million in Summit Therapeutics PLC $SMMT

August 31, 2026 | marketbeat.com

Beacon Pointe Advisors LLC Purchases Shares of 98,114 Summit Therapeutics PLC $SMMT

August 31, 2026 | marketbeat.com

Summit Therapeutics Inc.

August 30, 2026 | barrons.com

BlackRock Inc. Invests $138.84 Million in Summit Therapeutics PLC $SMMT

August 29, 2026 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Hold" from Analysts

August 28, 2026 | marketbeat.com

HC Wainwright Reiterates Neutral Rating for Summit Therapeutics (NASDAQ:SMMT)

August 28, 2026 | americanbankingnews.com

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

August 27, 2026 | zacks.com

Ivonescimab beats Imfinzi in Chinese biliary tract cancer trial

August 27, 2026 | thepharmaletter.comT

Deutsche Bank AG Makes New $3.49 Million Investment in Summit Therapeutics PLC $SMMT

August 27, 2026 | marketbeat.com

Summit Therapeutics (SMMT) Published Phase III HARMONi Results In The Lancet Oncology

August 27, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, SMMT, KRYS, and IONS Company Descriptions

Alumis NASDAQ:ALMS

$11.36 +1.01 (+9.76%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$11.49 +0.13 (+1.17%)

As of 05:06 AM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Ionis Pharmaceuticals NASDAQ:IONS

$58.13 -3.20 (-5.22%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$58.52 +0.39 (+0.68%)

As of 04:54 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Krystal Biotech NASDAQ:KRYS

$371.47 +2.24 (+0.61%)

As of 09/3/2026 04:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Summit Therapeutics NASDAQ:SMMT

$17.13 +2.53 (+17.33%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$16.94 -0.19 (-1.11%)

As of 05:29 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALMS, SMMT, KRYS, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALMS, SMMT, KRYS, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALMS, SMMT, KRYS, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, SMMT, KRYS, and IONS Company Descriptions

Alumis NASDAQ:ALMS

Ionis Pharmaceuticals NASDAQ:IONS

Krystal Biotech NASDAQ:KRYS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALMS, SMMT, KRYS, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALMS, SMMT, KRYS, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALMS, SMMT, KRYS, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, SMMT, KRYS, and IONS Company Descriptions

Alumis NASDAQ:ALMS

Ionis Pharmaceuticals NASDAQ:IONS

Krystal Biotech NASDAQ:KRYS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools